Theolytics has named Matilde Saggese as its new Chief Medical Officer, as the Oxford-based biotech company accelerates clinical development of its lead oncolytic immunotherapy, THEO-260.
Matilde will oversee clinical and regulatory strategy for Theolytics, including trials of THEO-260 in patients with platinum-resistant ovarian cancer. The therapy is currently being evaluated in the UK and US, with two different routes of administration – intravenous and intraperitoneal.
David Apelian, CEO, said: “I am thrilled to welcome Matilde as our new Chief Medical Officer. As a clinical-stage company, this is a crucial appointment for Theolytics and I am confident that with her extensive expertise in medical oncology in all phases of clinical development, Matilde will be instrumental in driving our clinical strategy for THEO-260 and our future clinical pipeline.”
Matilde brings over two decades of clinical experience in treating solid and haematological malignancies. She has held roles at Careggi University Hospital in Florence, the Royal Marsden Hospital and the Sarah Cannon Research Institute in London.
Her research background includes laboratory work at Cornell Medical Center and Memorial Sloan Kettering Cancer Center in New York state, as well as at the UCL Cancer Institute in London.
